Ongoing clinical trials in molecular imaging and radiotheranostics. Sorted by date of last update.
Comparing Retreatment of Lu-177-DOTATATE PRRT versus the Usual Treatment in Patients with Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
Phase 2
Last update: September 3
Lu-177-DOTA-EB-TATE in Adult Patients with Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Phase 1
REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE (REINITIATE)
Phase 4
Testing the Addition of Sunitinib Malate to Lutetium Lu-177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
A Study to Evaluate a New Way to Identify/Diagnose Tumours with Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use
Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu-177 Dotatate in Patients with Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial
Last update: September 2
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium Lu-177 PSMA RLT and Its Effect on Patients with Advanced Prostate Cancer, RECIPROCAL Trial
Phase 3
An Open-label Study Comparing Lutetium (Lu-177) Vipivotide Tetraxetan versus Observation in PSMA Positive OMPC. (PSMA-DC)
Last update: September 1
Lu-177-DOTATATE (Lutathera) in Combination with Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Study to Evaluate the Efficacy and Safety of Lu-177-NYM032 Injection in Participants with Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Last update: August 31